Sign in →

Test Code BAPS Bile Acid Profile, Serum


Ordering Guidance


This test is intended for use by research scientists. Approval must be obtained before ordering.



Specimen Required


Patient Preparation: Patient must be fasting for 12 to 14 hours.

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Evaluating the enterohepatic cycle consisting of the biliary system, intestine, portal circulation, and hepatocytes

 

Supporting researchers in need of free and conjugated values of all 20 bile acid species as well as total bile acid

Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Bile Acid Profile, S

Specimen Type

Serum

Specimen Minimum Volume

0.3 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 90 days
  Ambient  90 days
  Frozen  90 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK

Clinical Information

Bile acids are formed in the liver from cholesterol, conjugated primarily to glycine and taurine, stored and concentrated in the gallbladder, and secreted into the intestine after the ingestion of a meal. In the intestinal lumen, the bile acids serve to emulsify ingested fats and thereby promote digestion. During the absorptive phase of digestion, approximately 90% of the bile acids are reabsorbed.

 

The efficiency of the hepatic clearance of bile acids from portal blood maintains serum concentrations at low levels in normal persons. An elevated fasting level, due to impaired hepatic clearance, is a sensitive indicator of liver disease. Following meals, serum bile acid levels have been shown to increase only slightly in normal persons, but markedly in patients with various liver diseases, including cirrhosis, hepatitis, cholestasis, portal-vein thrombosis, Budd-Chiari syndrome, cholangitis, Wilson disease, and hemochromatosis. No increase in bile acids will be noted in patients with intestinal malabsorption. Metabolic hepatic disorders involving organic anions (eg, Gilbert disease, Crigler-Najjar syndrome, and Dubin-Johnson syndrome) do not cause abnormal serum bile acid concentrations.

 

The concentration of bile acids in serum is influenced by many different liver diseases due to the inability of the liver to efficiently extract circulating bile acids from portal blood.

 

In addition, bile acid levels are altered in several biochemical genetic conditions, such as peroxisomal biogenesis disorders (eg, Zellweger spectrum disorder) and disorders of bile acid synthesis (eg, D-bifunctional protein deficiency and alpha methyl-CoA racemase deficiency), due to the loss of specific enzymes important for bile acid metabolism.

 

This analysis includes a quantitative characterization of primary and secondary bile acids as well as 2 bile acid precursor species for the assessment of bile acid metabolism.

Reference Values

Chenodeoxycholic acid: ≤2.26 nmol/mL

Cholic acid: ≤2.74 nmol/mL

Deoxycholic acid: ≤2.84 nmol/mL

Dihydroxycholestanoic acid: ≤0.07 nmol/mL

Glycochenodeoxycholic acid: ≤5.14 nmol/mL

Glycocholic acid: ≤2.17 nmol/mL

Glycodeoxycholic acid: ≤3.88 nmol/mL

Glycohyodeoxycholic acid: ≤0.01 nmol/mL

Glycolithocholic acid: ≤0.11 nmol/mL

Glycoursodeoxycholic acid: ≤1.00 nmol/mL

Hyodeoxycholic acid: ≤0.12 nmol/mL

Lithocholic acid: ≤0.09 nmol/mL

Taurochenodeoxycholic acid: ≤0.80 nmol/mL

Taurocholic acid: ≤0.31 nmol/mL

Taurodeoxycholic acid: ≤0.78 nmol/mL

Taurohyodeoxycholic acid: ≤0.02 nmol/mL

Taurolithocholic acid: ≤0.04 nmol/mL

Tauroursodeoxycholic acid: ≤0.05 nmol/mL

Trihydroxycholestanoic acid: ≤1.73 nmol/mL

Ursodeoxycholic acid: ≤0.64 nmol/mL

Total bile acids: ≤19.00 nmol/mL

Day(s) Performed

Monday through Friday

Report Available

3 to 5 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

82542